Latest Lipase Stories

“Food Enzymes Market By Types (Carbohydrase, Protease, Lipase), Applications (Beverages, Dairy, Bakery), Sources (Microorganisms, Plants, Animals) & Geography - Global Trends & Forecasts To 2018” is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) June 16, 2013 Global food enzyme market is expected to reach $2.3 billion by 2018; North America is expected to lead the market, followed by Europe and Asia-Pacific. Asia-Pacific is the fastest...

AMSTERDAM, The Netherlands, November 2, 2012 /PRNewswire/ -- - Glybera [http://www.uniqure.com/uploads/Glybera 2pp Factsheet_lr.pdf ] becomes the first gene therapy approved by regulatory authorities in the Western world - First medication approved for patients with rare metabolic disorder Lipoprotein Lipase Deficiency - Commercial roll-out to begin second half of2013 - Validates uniQure's unique AAV-based...

Enzymes involved in breaking down fat can now be manipulated to work three times harder by turning on a molecular switch recently observed by chemists at the University of Copenhagen. Being able to control this chemical on/off button could have massive implications for curing diseases related to obesity including diabetes, cardio vascular disease, stroke and even skin problems like acne. But the implications may be wider. Possibly the most important discovery in enzymology The results...

redOrbit Staff & Wire Reports - Your Universe Online A European Union agency for the evaluation of medicinal products is recommending the approval of a gene therapy treatment for a rare disease, which would be the first time a treatment of this kind has received the regulatory go-ahead for use in the West, according to various reports published Friday. A statement released by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) officially...

AMSTERDAM, The Netherlands, July 20, 2012 /PRNewswire/ -- - First gene therapy in the Western world to reach important regulatory approval milestone, culminating 40 years of research - First therapy for LPL deficient patients, a severe disease with no alternative treatment - Validates uniQure's unique AAV-based gene therapy platform, consisting of a modular, plug-and-play vector system and unrivaled GMP manufacturing...

AMSTERDAM, July 7, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera(R)with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011....

ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the...

AMSTERDAM, May 20, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein. Glybera is a gene therapy product under development for the treatment of...

BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ -- - LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis - LPLchip(R) Identifies Patients who Could Benefit From Gene Therapy, Such as AMT's Glybera(R), Currently Under Review for EU Approval Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the...

New findings reported in the July issue of Cell Metabolism, a Cell Press publication, are offering new leads as to why some people might suffer from high levels of triglycerides. High triglycerides are a risk factor for atherosclerosis and cardiovascular disease. They can also lead to inflammation of the pancreas, the researchers said.The team led by Loren Fong and Stephen Young of the University of California, Los Angeles, has identified the component responsible for bringing a key...